Press Releases Press Releases Year None2023202220212020201920182017 Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates Mar 23, 2023 Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets Jan 24, 2023 Print Page Contact IR RSS Feeds E-mail Alerts
Year None2023202220212020201920182017 Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates Mar 23, 2023 Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets Jan 24, 2023
Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates Mar 23, 2023
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets Jan 24, 2023
